文献速递疝与腹壁外科围术期管理与 ERAS

Zynrelef(布比卡因与美洛昔康)在腹腔镜腹膜前腹股沟疝修补术中消除阿片类药物需求的应用

Use of Zynrelef (bupivacaine and meloxicam) to eliminate the need for opioids in laparoscopic pre-peritoneal inguinal hernia repairs.
PubMed 文献 · Surg Endosc · 2026-01-22

本研究观察43例接受TEP手术的患者在术中使用Zynrelef后的阿片类药物使用情况。结果显示84.6%的患者未接受阿片类药物处方,术后疼痛评分逐日下降,结论认为Zynrelef可提供充分镇痛并减少阿片类药物使用。

要点

  • TEP术中使用Zynrelef后84.6%患者未使用阿片类药物。
  • 术后疼痛评分从即刻3.51降至POD10的1.11。
  • 对乙酰氨基酚和布洛芬平均停药时间为术后6.23天和5.63天。

核心结论

  • TEP术中使用Zynrelef可提供充分镇痛并减少阿片类药物使用。

研究设计与样本

  • 单臂观察性研究,纳入43例(42男1女)年龄32-79岁拟行TEP的患者。
  • 在关窗前经最下方5mm trocar于腹膜前间隙给予7-14 mL Zynrelef。
  • 术后随访10天记录药物使用和疼痛水平。

主要发现

  • 39例完成研究,6例(15.4%)接受阿片类药物处方,33例(84.6%)未接受。
  • 术后即刻平均疼痛评分3.51(SD±1.94),POD1为2.63(SD±1.73),POD3为2.51(SD±1.57),POD5为2.00(SD±1.34),POD10为1.11(SD±0.98)。
  • 对乙酰氨基酚和布洛芬平均停药时间分别为术后6.23天和5.63天,6例使用阿片类药物者平均停药时间5天。

临床怎么用

  • TEP术中可考虑在腹膜前间隙使用Zynrelef作为多模式镇痛的一部分以减少阿片类药物需求。
  • 术后应指导患者规律使用对乙酰氨基酚和布洛芬,疼痛评分大于6/10时可考虑阿片类药物。

局限性

  • 单臂设计无对照组,样本量较小(39例完成),随访仅10天。
  • 排除2例多发疝和2例失访,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inguinal hernia repairs are a common procedure, occurring in 800,000 patients across the United States and 20 million patients worldwide annually (Simmons et al. in Hernia 22:1-165, 2018;Knight et al. in Surgery 166:752-757, 2019;Schirle et al. in Syst Rev 9:139, 2020;). Currently, the most common form of pain management used by providers has been opioids despite unwanted side effects and dependence risk. Studies show up to 71% of patients undergoing TEP are prescribed opioids for pain management (Brummett et al. in JAMA Surg 152, 2017). The growing national misuse of opioids stresses the importance of alternative pain management options. Zynrelef has proven effective for managing post-op pain up to 72 h following several other surgeries but has not been effectively tested in TEP(s) (Hill et al. in Ann Surg 265:709-714, 2017; Provisional Drug Overdose Death Counts. National Vital Statistics System. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.;Hamilton et al. in Anaesthesia 78:170, 2023;). This study observed opioid usage in patients following the use of Zynrelef during TEP procedures to determine if Zynrelef proves to be an effective alternative to opioid usage. METHODS: 43 subjects (42 male and 1 female) between ages 32 and 79 years, scheduled to undergo TEP, were enrolled in the study and received between 7 and 14 mL's of Zynrelef prior to wound closure in the pre-peritoneal space via the most inferior 5 mm trocar. Subjects were instructed to take multimodal agents (Acetominophen1000 mg Q6 and Ibuprofen 800 mg q6) and given a prescription for opioids if their NRS pain score was greater than 6/10 in recovery. Subjects were then followed for 10 days after surgery to observe and record all medication usage and pain levels. RESULTS: 39 subjects completed the study period (2 subjects excluded due to multiple hernias found during surgery and 2 lost to follow-up). 6 (15.4%) subjects received an opioid prescription, 33 (84.6%) did not. Mean pain immediately following surgery was 3.51 (SD ± 1.94), 2.63(SD ± 1.73) on POD1, 2.51(SD ± 1.57) on POD3, 2.00(SD ± 1.34) on POD5, and 1.11(SD ± 0.98) on POD 10. Mean discontinuation of acetaminophen and ibuprofen was 6.23 and 5.63 days post-op, respectively. Of the six subjects who received opioids post-op the mean time to opioid discontinuation was 5 days. CONCLUSION: Results of this study display adequate pain management following TEP procedures with the use of Zynrelef and a reduction in the use of opioids compared to patients undergoing TEP without Zynrelef. The findings from this study are in alignment with findings from other studies such as the HOPE trial in which Zynrelef was used in patients with open inguinal hernias and displayed an opioid-free rate of 91%.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Beard CA, Beard T, Devenny ML, et al. Use of Zynrelef (bupivacaine and meloxicam) to eliminate the need for opioids in laparoscopic pre-peritoneal inguinal hernia repairs. Surg Endosc. 2026. PMID: 41571990. doi:10.1007/s00464-026-12575-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。